Carcinosarcoma of the Breast With An Unusual Secretory Carcinoma as the Carcinomatous Component

Srinivas, V.; Harjai, MM; Subramanya, H; Rajaram, T; Rai, Ramji

doi:10.1016/s0377-1237(04)80027-3

Cited by 2 publications

(2 citation statements)

References 2 publications

(3 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lastly, we point out the previously‐published case described as “carcinosarcoma of the breast with an unusual secretory carcinoma as the carcinomatous component” reported in 2004 by Srinivas et al that showed several features in common with the present case 30 . While the diagnosis of secretory carcinoma in their report was neither confirmed by ancillary molecular testing nor supported by an immunohistochemical panel, it is still possible that their case represents another tumor like ours.…”

Section: Discussioncontrasting

confidence: 50%

Dedifferentiated secretory breast carcinoma with fibrosarcomatous features harboring an ETV6‐NTRK3 fusion in both components

Weisman

2020

Genes Chromosomes & Cancer

View full text Add to dashboard Cite

Secretory carcinomas are low‐grade translocation‐driven carcinomas occurring in patients over a wide age range. These tumors most frequently arise in the breast and salivary gland, but may occasionally arise at other anatomic sites, such as the skin, the thyroid gland or the upper or lower respiratory tract. In concert with their low‐grade morphology, secretory carcinomas most often follow an indolent clinical course. However, rare cases have shown dedifferentiation (also known as high‐grade transformation) and aggressive clinical behavior. To date, the dedifferentiated component in all molecularly confirmed cases of secretory carcinoma has taken the form of a high‐grade carcinoma. Here we present a case of an ETV6‐NTRK3 fusion‐positive secretory carcinoma of the breast with sarcomatous dedifferentiation. The sarcomatous component showed an infantile or adult fibrosarcoma‐like morphology including a herringbone fascicular pattern and a hemangiopericytic vascular pattern. By immunohistochemistry, the sarcomatous component showed focal CD34 immunoreactivity and loss of all of the markers expressed in the conventional secretory carcinoma component, including SOX10, S100, GATA‐3, AE1/AE3 and E‐cadherin. Fluorescence in situ hybridization analysis revealed that the sarcomatous component retained the ETV6‐NTRK3 fusion, but also acquired homozygous deletion of CDKN2A. The tumor followed an aggressive clinical course and the patient eventually succumbed to her disease 14 months after diagnosis. The histomorphologic and molecular genetic features of this tumor are discussed, including its ability to mimic kinase‐rearranged infantile or adult fibrosarcomas at extramammary sites and the theragnostic importance of its distinction from conventional metaplastic spindle cell carcinomas in the breast.

show abstract

Section: Discussioncontrasting

confidence: 50%

Dedifferentiated secretory breast carcinoma with fibrosarcomatous features harboring an ETV6‐NTRK3 fusion in both components

Weisman

2020

Genes Chromosomes & Cancer

View full text Add to dashboard Cite

show abstract

“…Carcinosarcoma (CS) breast is an extremely rare malignancy, accounting for about 0.1% of all primary breast tumors. [1] CS is defined as tumor exhibiting both carcinomatous and sarcomatous components (malignant nonepithelial component of mesenchymal origin), without evidence of a transition zone between the two elements. [2] The exact cell of the origin of CS is not known, but it is believed to be sarcomatoid metaplasia of carcinoma cells.…”

Section: Introductionmentioning

confidence: 99%

Carcinosarcoma (Metaplastic Carcinoma) Breast: A Rare and Aggressive Primary – Report of Two Cases with Review of Literature

Singh

Bhowmik

2018

Indian Journal of Medical and Paediatric Oncology

View full text Add to dashboard Cite

Carcinosarcoma (CS) also known as metaplastic carcinoma of the breast is a rare and aggressive type of malignancy with controversial origin. Currently, there are no standard treatment guidelines outlined, owing to the rarity of the disease, but according to the available literature, surgery followed by adjuvant radiation therapy has the greatest benefit. We are presenting two cases of CS of breast developing metastasis. One of the cases presented with lung metastasis during the course of follow-up and responded significantly to chemotherapy, and the other is currently receiving chemotherapy. The cases are being presented here along with the literature review enlightening the current knowledge and available treatment options.

show abstract

Carcinosarcoma of the Breast With An Unusual Secretory Carcinoma as the Carcinomatous Component

Cited by 2 publications

References 2 publications

Dedifferentiated secretory breast carcinoma with fibrosarcomatous features harboring an ETV6‐NTRK3 fusion in both components

Dedifferentiated secretory breast carcinoma with fibrosarcomatous features harboring an ETV6‐NTRK3 fusion in both components

Carcinosarcoma (Metaplastic Carcinoma) Breast: A Rare and Aggressive Primary – Report of Two Cases with Review of Literature

Contact Info

Product

Resources

About